Universitätsklinikum Aachen

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Nationwide Children's Hospital· Source

• Not yet recruiting

  Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

  2024-517295-37-00· Phase 3· University Of Cologne· Source

• Not yet recruiting

  PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%

  NCT07877584· Phase 3· German Cancer Research Center· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

  NCT07789574· Phase 2· Thomas Ernst, Prof. Dr. med.· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder

  2024-510873-11-00· Phase 2· Apurano Pharmaceuticals GmbH· Source

• Recruiting

  A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

  NCT07843472· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

  NCT07775924· Phase 2· Novartis Pharmaceuticals· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source

• Not yet recruiting

  NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

  NCT07178730· Phase 3· Women's Cancer Study Group GmbH· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma

  NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Not yet recruiting

  First-in-Women Study Evaluating the Safety of Lutetium-177 Radioligand Therapy in Metastatic Triple-Negative Breast Cancer

  2025-524027-49-00· Phase 1· Universitaetsklinikum Aachen AöR· Source

• Not yet recruiting

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· Phase 3· University of Heidelberg Medical Center· Source

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07690371· Phase 3· Nektar Therapeutics· Source

• Recruiting

  PREFer

  NCT06916416· Phase 2· University Of Cologne· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

  NCT07585890· University Medical Center Groningen· Source

• Recruiting

  Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria

  2025-522878-36-00· Phase 3· Celldex Therapeutics Inc.· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

  NCT07405801· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  NCT07355218· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke - the LOCAL trial

  2024-516544-26-00· Phase 2· Universitaetsklinikum Heidelberg AöR· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants

  2025-521762-99-00· Phase 3· University Medical Center Hamburg-Eppendorf· Source

• Not yet recruiting

  A Study on Remote Health Support for Patients With Heart Failure.

  NCT07440472· Universitat Internacional de Catalunya· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma

  2022-500676-59-00· Phase 2· GPOH gGmbH· Source

• Recruiting

  STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

  NCT07280585· Phase 3· University of Cologne· Source

• Active, not recruiting

  Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics

  2024-519836-18-00· Phase 3· Newron Pharmaceuticals S.p.A.· Source

• Recruiting

  Development of the PTSD-iMPACT to Measure PTSD-Related Functional Impairment in Children and Adolescents - A Validation Study in Switzerland and Germany

  NCT07368166· University Children's Hospital, Zurich· Source

• Recruiting

  A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and Docetaxel in Patients with Recurrent Metastatic Head and Neck Cancer - AVETUX-HN

  2025-521738-27-00· Phase 2· Charite Universitaetsmedizin Berlin KöR· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source

• Recruiting

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· Phase 3· AstraZeneca· Source

• Recruiting

  Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.

  2024-516906-47-00· Phase 2/3· Daiichi Sankyo Inc.· Source

• Recruiting

  Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

  NCT07260175· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT07197307· Phase 2· Universität Münster· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· ONL Therapeutics· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

Showing 50 of 200.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers21 recruiting
• Acute myeloid leukaemia10 recruiting
• Acute lymphoblastic leukaemia7 recruiting
• Liver and biliary tract cancer7 recruiting
• Multiple myeloma6 recruiting
• Chronic myeloid leukaemia5 recruiting
• Heart failure5 recruiting
• Lung cancer5 recruiting
• Metastatic breast cancer5 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Liver cirrhosis4 recruiting
• Prostate cancer4 recruiting
• Ulcerative colitis4 recruiting
• Epilepsy3 recruiting
• Huntington's disease3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Obesity3 recruiting
• Ovarian cancer3 recruiting
• Pancreatic cancer3 recruiting
• Stroke3 recruiting
• Alzheimer disease2 recruiting
• Bronchiectasis2 recruiting
• Follicular lymphoma2 recruiting
• Friedreich ataxia2 recruiting
• Head and neck cancer2 recruiting
• Hidradenitis suppurativa2 recruiting
• Hodgkin lymphoma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Neuroblastoma2 recruiting
• Sarcoma2 recruiting
• Triple-negative breast cancer2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic spontaneous urticaria1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Coeliac disease1 recruiting
• Depression1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Lichen planus1 recruiting
• Lupus (SLE)1 recruiting
• Macular degeneration1 recruiting
• Multiple sclerosis1 recruiting
• Nephrotic syndrome1 recruiting
• Polycystic kidney disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Sickle cell disease1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  Impact of Chewing Gum on FeNO Levels in Patients With Bronchial Asthma

  NCT07053956· RWTH Aachen University· Source

• Withdrawn

  Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia

  NCT06560346· Friedreich's Ataxia Research Alliance· Source

• Completed

  Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

  NCT06855056· European Foundation for Study of Chronic Liver Failure· Source

• Completed

  An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures

  2024-517061-16-01· Phase 2· Praxis Precision Medicines Inc.· Source

• Completed

  With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia

  2024-518971-76-00· Phase 2· Heidelberg University· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Completed

  A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

  NCT06615921· Takeda· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source

• Completed

  Comparison of 18F-Fluciclovine PET versus 18F-Fluoroethyltyrosine PET in patients with newly diagnosed cerebral gliomas, recurrent cerebral gliomas and brain metastases – an open label single centre single arm prospective basket trial

  2023-507786-26-00· Phase 2· Universitaetsklinikum Aachen AöR· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Completed

  A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

  NCT06431763· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· Phase 2· Sutro Biopharma Inc.· Source

• Active, not recruiting

  Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

  NCT06216158· Phase 3· University of Heidelberg Medical Center· Source

• Completed

  Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

  NCT06182085· Phase 2· PRInnovation GmbH· Source

• Completed

  Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)

  2022-503148-41-00· Phase 2· Prinnovation GmbH· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  Safety, tolerability, and efficacy of ACOU085 for prevention of hearing loss in testicular cancer patients receiving cisplatin

  NCT06521190· Phase 2· Acousia Therapeutics GmbH· Source

• Completed

  A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-505558-16-00· Phase 3· Almirall S.A.· Source

• Completed

  V-A ECMO AUTO Mode Registry

  NCT05759377· Abiomed Inc.· Source

• Completed

  Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)

  2022-502040-13-00· Phase 2· University of Leipzig· Source

• Completed

  A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)

  NCT05278104· Boehringer Ingelheim· Source

• Completed

  Venetoclax After TKI to Target Persisting Stem Cells in CML

  NCT05701215· Phase 2· Thomas Ernst, PD Dr. med.· Source

• Completed

  Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)

  2024-515660-31-00· Phase 2· Universitaetsklinikum Schleswig-Holstein AöR· Source

• Completed

  Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)

  NCT05675319· Phase 3· University Medical Center Hamburg-Eppendorf· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Phase 2· Hoffmann-La Roche· Source

• Completed

  EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.

  2023-504832-16-00· Phase 2· Genmab A/S· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Inducta

  2023-509837-37-00· Phase 2· Universitaet Des Saarlandes· Source

• Completed

  A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

  NCT05103657· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  A Long-term Extension Study of Ustekinumab in Pediatric Participants

  NCT05092269· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Usability and Feasibility of a Personalized, Web-based Education and Self-management Approach for Patients With Chronic Heart Failure Across Four European Sites

  NCT04699253· Maastricht University Medical Center· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

  NCT04746924· Phase 3· Beigene Ltd.· Source

• Completed

  Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04833114· Phase 3· GWT-TUD GmbH· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT04673357· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT04630028· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

  NCT04578834· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

  NCT04338399· Phase 3· Adlai Nortye Biopharma Co., Ltd.· Source

• Completed

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· Phase 3· AbbVie· Source

• Completed

  Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

  NCT04263584· Phase 2· University Hospital Muenster· Source

• Completed

  Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

  NCT04227522· Phase 3· North Eastern German Society of Gynaecological Oncology· Source

• Completed

  Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

  NCT04375605· Phase 3· Universitätsmedizin Mannheim· Source

• Completed

  Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy

  NCT04351256· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

  2024-515827-12-00· Phase 1· AvenCell Europe GmbH· Source

• Completed

  Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

  NCT03989206· Phase 3· Galderma R&D· Source

• Completed

  CIRCULATE

  NCT04089631· Phase 3· Technische Universitat Dresden· Source

Showing 50 of 74.

Conditions

Diseases this institution publishes on or runs trials for.

• Chronic kidney disease71 works · 7 trials
• Fatty liver disease (MASLD/MASH)29 works · 1 trial
• IgA nephropathy19 works · 7 trials
• Aortic aneurysm11 works · 0 trials
• Chronic myeloid leukaemia6 works · 12 trials
• Polycystic kidney disease4 works · 1 trial
• ANCA-associated vasculitis4 works · 0 trials
• Aplastic anaemia3 works · 0 trials